bluebird bio (BLUE) said Friday that it agreed to be acquired by funds managed by The Carlyle Group (CG) and SK Capital Partners.
Under the terms of the deal, bluebird shareholders will receive $3.00 per share in cash and a contingent value right of $6.84 per share, payable in cash if bluebird's current product portfolio earns $600 million in net sales in any trailing 12-month period before or ending Dec. 31, 2027. The contingency potentially raises the acquisition price to $9.84 per share.
The company expects David Meek, former chief executive of Mirati Therapeutics and Ipsen, to be named CEO of bluebird when the deal closes. It also said Carlyle and SK Capital will provide the company with primary capital for commercial delivery of gene therapies for patients with sickle cell disease, thalassemia, and cerebral adrenoleukodystrophy.
Trading in shares of bluebird bio on the Nasdaq stock market has been suspended and is expected to resume at 8:00 ET.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。